Therapeutic Effect of Desogestrel on Ventilatory Control in Patients With Congenital Central Hypoventilation Syndrome
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Background: Congenital Central Hypoventilation Syndrome (CCHS) is a rare disorder of automatic control of breathing. This disease can manifest as early as birth. Patients with this disease have a fundamental lack of central drive breathing. They do not mount any responses to hypoxia or hypercapnia during sleep or wakefulness. This places them at risk of injury or death whenever they are not consciously breathing. They require lifelong assisted ventilation while sleeping, and some while awake. Progesterone is a known respiratory stimulant in normal individuals, and it has been shown in one study of 2 patients that this drug may improve CO2 responsiveness in patients with CCHS. However, this observation requires confirmation.
Hypothesis: Exogenous progesterone (in oral contraception pills) will improve CO2 responsivity by hyperoxic hypercapnic ventilatory response testing, hypoxic responsivity using 5-breath nitrogen breathing, hyperoxic ventilatory response while breathing 100% oxygen, and improve spontaneous ventilation during sleep in CCHS females >15-years of age. The progesterone will also depress ventilatory response using a hyperoxia test.
Study Methodology: Baseline measures of CO2 and oxygen responsivity, and spontaneous ventilation during sleep, will be performed at baseline and after 3-weeks of taking a progesterone containing oral contraceptive agent. CO2 responsivity will be measured using a hyperoxic hypercapnic ventilatory response test. Hypoxic responsivity will be measured using a 5-breath 100% nitrogen breathing test. Hyperoxic responsivity will be measured by having subjects breathe 100% oxygen for 2-minutes. Subjects will perform an overnight polysomnogram to assess adequacy of gas exchange during spontaneous breathing while asleep. A progesterone containing oral contraception pill will then be given for 3-weeks, and the above measures repeated. Serum progesterone will be measured at baseline and at the time of study.
| Condition | Intervention |
|---|---|
|
Congenital Central Hypoventilation Syndrome |
Drug: Desogestrel |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Single Blind (Subject) Primary Purpose: Treatment |
| Official Title: | Therapeutic Effect of Desogestrel on Ventilatory Control in Patients With Congenital Central Hypoventilation Syndrome |
- Minute ventilation [ Time Frame: 3 weeks ] [ Designated as safety issue: Yes ]
- Time to requirement of assisted ventilation [ Time Frame: 3 weeks ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 8 |
| Study Start Date: | February 2012 |
| Estimated Primary Completion Date: | December 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Females with CCHS > 16 years old on desogetrel |
Drug: Desogestrel
Reclipsen oral contraceptive pill with 0.03mg ethinyl estradiol and 0.15mg desogestrel
|
Eligibility| Ages Eligible for Study: | 16 Years to 50 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- diagnosed congenital central hypoventilation syndrome (CCHS)
- female
- greater than or equal to 16 years of age
Exclusion Criteria:
- less than 16 years of age
- male
- pregnant
- poor adherence to medications
- inability to perform pulmonary maneuvers for tests
- contraindications to oral contraceptives
- pulmonary hypertension
Contacts and Locations| Contact: Thomas Keens, MD | 323-361-2101 | |
| Contact: Douglas LI, MD | 323-361-2101 |
| United States, California | |
| Children's Hospital Los Angeles | |
| Los Angeles, California, United States, 90027 | |
| Children's Hospital Los Angeles | Not yet recruiting |
| Los Angeles, California, United States, 90027 | |
| Contact: Thomas Keens, MD 323-361-2101 | |
More Information
No publications provided
| Responsible Party: | Thomas Keens, MD, Senior Investigator, Children's Hospital Los Angeles |
| ClinicalTrials.gov Identifier: | NCT01500473 History of Changes |
| Other Study ID Numbers: | CCI-11-00057 |
| Study First Received: | December 22, 2011 |
| Last Updated: | February 13, 2012 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Hypoventilation Respiratory Insufficiency Sleep Apnea, Central Respiration Disorders Respiratory Tract Diseases Signs and Symptoms, Respiratory Signs and Symptoms Sleep Apnea Syndromes Apnea Sleep Disorders, Intrinsic Dyssomnias Sleep Disorders Nervous System Diseases |
Desogestrel Progestins Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Pharmacologic Actions Contraceptives, Oral, Synthetic Contraceptives, Oral Contraceptive Agents, Female Contraceptive Agents Reproductive Control Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on June 13, 2013